Observational Study in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia (CML) Treated With Nilotinib: Follow-up of the Italian Patients. GIMEMA Study CML0609
Phase of Trial: Phase IV
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms GIMEMA Study
- 21 Mar 2018 Planned End Date changed from 1 Feb 2018 to 1 May 2018.
- 21 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 May 2018.
- 23 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.